{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:49:53Z","timestamp":1791492593045,"version":"4.3.4"},"publisher-location":"Berlin, Heidelberg","reference-count":109,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_846","type":"book-chapter","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:08:23Z","timestamp":1791490103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing SGLT2 Inhibitors Beyond Diabetes: Emerging Roles in Cancer Prevention and Therapy"],"prefix":"10.1007","author":[{"given":"Aarajana","family":"Shrestha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idelxy","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn Cruz","family":"Lopategui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Deb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"846_CR1","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112455","volume":"145","author":"AM Abdelhamid","year":"2022","unstructured":"Abdelhamid AM, Saber S, Youssef ME, Gaafar AGA, Eissa H, Abd-Eldayem MA et al (2022) Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: emerging approach for new application. Biomed Pharmacother 145:112455","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"846_CR2","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.4103\/jcrt.JCRT_963_19","volume":"17","author":"MK Abdel-Rafei","year":"2021","unstructured":"Abdel-Rafei MK, Thabet NM, Rashed LA, Moustafa EM (2021) Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: signal transduction between PI3K\/AKT\/GSK-3\u03b2\/mTOR and Wnt\/\u03b2-catenin pathways;: in vitro. J Cancer Res Ther 17(6):1404\u20131418","journal-title":"J Cancer Res Ther"},{"issue":"10","key":"846_CR3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2174\/138161208784139765","volume":"14","author":"R Abe","year":"2008","unstructured":"Abe R, Yamagishi S-i (2008) AGE-RAGE system and carcinogenesis. Curr Pharm Des 14(10):940\u2013945","journal-title":"Curr Pharm Des"},{"key":"846_CR4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1539870","volume":"16","author":"AE Abou Warda","year":"2025","unstructured":"Abou Warda AE, Flohr RM, Sarhan RM, Salem MN, Salem HF, Moharram AN et al (2025) Genetic polymorphisms in SLC5A2 are associated with clinical outcomes and dapagliflozin response in heart failure patients. Front Pharmacol 16:1539870","journal-title":"Front Pharmacol"},{"issue":"1","key":"846_CR5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.sjbs.2019.06.015","volume":"27","author":"M Abudawood","year":"2020","unstructured":"Abudawood M, Tabassum H, Almaarik B, Aljohi A (2020) Interrelationship between oxidative stress, DNA damage and cancer risk in diabetes (Type 2) in Riyadh, KSA. Saudi J Biol Sci 27(1):177\u2013183","journal-title":"Saudi J Biol Sci"},{"issue":"1","key":"846_CR6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s42003-022-03422-9","volume":"5","author":"ND Akingbesote","year":"2022","unstructured":"Akingbesote ND, Norman A, Zhu W, Halberstam AA, Zhang X, Foldi J et al (2022) A precision medicine approach to metabolic therapy for breast cancer in mice. Commun Biol 5(1):478","journal-title":"Commun Biol"},{"issue":"1","key":"846_CR7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s42003-023-05289-w","volume":"6","author":"A Ali","year":"2023","unstructured":"Ali A, Mekhaeil B, Biziotis O-D, Tsakiridis EE, Ahmadi E, Wu J et al (2023) The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun Biol 6(1):919","journal-title":"Commun Biol"},{"issue":"1","key":"846_CR8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s11658-024-00599-1","volume":"29","author":"C Anastasio","year":"2024","unstructured":"Anastasio C, Donisi I, Del Vecchio V, Colloca A, Mele L, Sardu C et al (2024) SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells. Cell Mol Biol Lett 29(1):80","journal-title":"Cell Mol Biol Lett"},{"issue":"2","key":"846_CR9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.61186\/armaghanj.29.2.172","volume":"29","author":"E Azargun","year":"2024","unstructured":"Azargun E, Gheitasi I, Sadeghi H, Panahi Kokhdan I, Azizi M, Akbari G (2024) Effect of empagliflozin on hepatotoxicity induced by cyclophosphamide in male rats. Armaghane Danesh 29(2):172\u2013184","journal-title":"Armaghane Danesh"},{"issue":"7","key":"846_CR10","volume":"11","author":"D Basak","year":"2023","unstructured":"Basak D, Gamez D, Deb S (2023) SGLT2 inhibitors as potential anticancer agents. Biomedicine 11(7):1867","journal-title":"Biomedicine"},{"issue":"8","key":"846_CR11","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s00044-024-03274-4","volume":"33","author":"RL Bassett","year":"2024","unstructured":"Bassett RL, Gallo G, Le K-PN, Volino LR (2024) Bexagliflozin: a comprehensive review of a recently approved SGLT2 inhibitor for the treatment of type 2 diabetes mellitus. Med Chem Res 33(8):1354\u20131367","journal-title":"Med Chem Res"},{"key":"846_CR12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106039","volume":"175","author":"R Benedetti","year":"2022","unstructured":"Benedetti R, Benincasa G, Glass K, Chianese U, Vietri MT, Congi R et al (2022) Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacol Res 175:106039","journal-title":"Pharmacol Res"},{"issue":"1","key":"846_CR13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, P\u00e9rez-Gracia JL et al (2019) Cytokines in clinical cancer immunotherapy. Br J Cancer 120(1):6\u201315","journal-title":"Br J Cancer"},{"issue":"6","key":"846_CR14","first-page":"863","volume":"6","author":"AW Bhatti","year":"2024","unstructured":"Bhatti AW, Patel R, Dani SS, Khadke S, Makwana B, Lessey C et al (2024) SGLT2i and primary prevention of cancer therapy\u2013related cardiac dysfunction in patients with diabetes. Cardio-Oncology 6(6):863\u2013875","journal-title":"Cardio-Oncology"},{"issue":"24","key":"846_CR15","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2174\/0115680266371287250402051235","volume":"25","author":"RP Bhole","year":"2025","unstructured":"Bhole RP, Maldhure GS, Kapare H, Labhade SD, Gurav SS (2025) Exploring SGLT2 inhibitors\u2019 activity in breast cancer: an overview. Curr Top Med Chem 25(24):2864\u20132887","journal-title":"Curr Top Med Chem"},{"issue":"11","key":"846_CR16","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/1878-0261.13508","volume":"17","author":"OD Biziotis","year":"2023","unstructured":"Biziotis OD, Tsakiridis EE, Ali A, Ahmadi E, Wu J, Wang S et al (2023) Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1\u03b1. Mol Oncol 17(11):2235\u20132256","journal-title":"Mol Oncol"},{"issue":"3","key":"846_CR17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2125.2012.04391.x","volume":"75","author":"DW Boulton","year":"2013","unstructured":"Boulton DW, Kasichayanula S, Keung CF, Arnold ME, Christopher LJ, Xu X et al (2013) Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol 75(3):763\u2013768","journal-title":"Br J Clin Pharmacol"},{"key":"846_CR18","unstructured":"Brenzavvy (Bexagliflozin) Prescribing Information. U.S. FDA Website. [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/214373s001lbl.pdf (accessed on 8 Dec 2025)"},{"issue":"12","key":"846_CR19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M (2020) SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 17(12):761\u2013772","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"846_CR20","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1007\/s00210-025-04132-9","volume":"398","author":"A Cumao\u011flu","year":"2025","unstructured":"Cumao\u011flu A, Akdeniz SN, Karzoon A, Alaama M, Yerer MB (2025) Effects of empagliflozin and its combination with docetaxel on LNCaP and DU-145 prostate cancer cell lines: cytotoxicity and molecular pathway analysis. Naunyn Schmiedeberg's Arch Pharmacol 398(10):13819\u201313831","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"4","key":"846_CR21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/cpdd.162","volume":"4","author":"D Devineni","year":"2015","unstructured":"Devineni D, Murphy J, Wang SS, Stieltjes H, Rothenberg P, Scheers E et al (2015) Absolute oral bioavailability and pharmacokinetics of canagliflozin: a microdose study in healthy participants. Clin Pharmacol Drug Dev 4(4):295\u2013304","journal-title":"Clin Pharmacol Drug Dev"},{"key":"846_CR22","doi-asserted-by":"crossref","unstructured":"Ding L, Chen X, Zhang W, Dai X, Guo H, Pan X et al (2023) Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. J Clin Invest 133(1)","DOI":"10.1172\/JCI154754"},{"issue":"1","key":"846_CR23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.55730\/1300-0144.5943","volume":"55","author":"\u015eE Do\u011fan","year":"2025","unstructured":"Do\u011fan \u015eE, Ku\u015fkonmaz \u015eM, Celepli P, \u015eenes M, H\u00fcc\u00fcmeno\u011flu S, \u00c7ulha C (2025) Empagliflozin effects on cyclophosphamide-induced neurotoxicity in rats without diabetes. Turkish J Med Sci 55(1):65\u201371","journal-title":"Turkish J Med Sci"},{"issue":"4","key":"846_CR24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6139","volume":"4","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Eneanya ND, Essien U, Julien H, Nathan AS et al (2021) Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw Open 4(4):e216139","journal-title":"JAMA Netw Open"},{"issue":"6","key":"846_CR25","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acsptsci.0c00144","volume":"3","author":"SG Eliaa","year":"2020","unstructured":"Eliaa SG, Al-Karmalawy AA, Saleh RM, Elshal MF (2020) Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mTOR pathway and inhibition of calmodulin: in vitro and molecular docking studies. ACS Pharmacol Transl Sci 3(6):1330\u20131338","journal-title":"ACS Pharmacol Transl Sci"},{"key":"846_CR26","unstructured":"FARXIGA\u00ae (dapagliflozin) Prescribing Information. U.S. Food and Drug Administration. [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202293s020lbl.pdf (accessed on 8 Dec 2025)"},{"issue":"11","key":"846_CR27","doi-asserted-by":"crossref","first-page":"16131","DOI":"10.1007\/s00210-025-04098-8","volume":"398","author":"HM Fayed","year":"2025","unstructured":"Fayed HM, Asaad GF, Elbaset MA, Sharaf OA, Mahmoud SS, Amin MM et al (2025) Therapeutic efficacy of canagliflozin against hepatocarcinogenesis induced by CDD\/DEN\/TAA in a rat model: regulation of AMPK\/HIF-1\u03b1\/YAP-1\/TAZ signaling pathways. Naunyn Schmiedeberg's Arch Pharmacol 398(11):16131\u201316148","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"9","key":"846_CR28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/jcph.506","volume":"55","author":"S Francke","year":"2015","unstructured":"Francke S, Mamidi RN, Solanki B, Scheers E, Jadwin A, Favis R et al (2015) In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol 55(9):1061\u20131072","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"846_CR29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1152\/physrev.00030.2014","volume":"95","author":"EJ Gallagher","year":"2015","unstructured":"Gallagher EJ, LeRoith D (2015) Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev 95(3):727\u2013748","journal-title":"Physiol Rev"},{"issue":"10","key":"846_CR30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26104780","volume":"26","author":"A Greco","year":"2025","unstructured":"Greco A, Canale ML, Quagliariello V, Oliva S, Tedeschi A, Inno A et al (2025) SGLT2 inhibitors in cancer patients: a comprehensive review of clinical, biochemical, and therapeutic implications in cardio-oncology. Int J Mol Sci 26(10):4780","journal-title":"Int J Mol Sci"},{"issue":"1","key":"846_CR31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI (2019) Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51(1):27\u201341","journal-title":"Immunity"},{"issue":"5","key":"846_CR32","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"issue":"4","key":"846_CR33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrm3311","volume":"13","author":"DG Hardie","year":"2012","unstructured":"Hardie DG, Ross FA, Hawley SA (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13(4):251\u2013262","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"846_CR34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40262-015-0307-x","volume":"55","author":"E Hoeben","year":"2016","unstructured":"Hoeben E, De Winter W, Neyens M, Devineni D, Vermeulen A, Dunne A (2016) Population pharmacokinetic modeling of canagliflozin in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 55(2):209\u2013223","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"846_CR35","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.celrep.2019.07.027","volume":"28","author":"M-H Hsieh","year":"2019","unstructured":"Hsieh M-H, Choe JH, Gadhvi J, Kim YJ, Arguez MA, Palmer M et al (2019) p63 and SOX2 dictate glucose reliance and metabolic vulnerabilities in squamous cell carcinomas. Cell Rep 28(7):1860\u201378. e9","journal-title":"Cell Rep"},{"key":"846_CR36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116140","volume":"223","author":"H Huang","year":"2024","unstructured":"Huang H, Kung F-L, Huang Y-W, Hsu C-C, Guh J-H, Hsu L-C (2024) Sensitization of cancer cells to paclitaxel-induced apoptosis by canagliflozin. Biochem Pharmacol 223:116140","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"846_CR37","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41419-019-1646-6","volume":"10","author":"M-H Hung","year":"2019","unstructured":"Hung M-H, Chen Y-L, Chen L-J, Chu P-Y, Hsieh F-S, Tsai M-H et al (2019) Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced \u03b2-catenin activation. Cell Death Dis 10(6):420","journal-title":"Cell Death Dis"},{"key":"846_CR38","unstructured":"IBM Micromedex. IBM Micromedex Drug Interactions. IBM Watson Health. [Available from: https:\/\/www.micromedexsolutions.com (accessed on 3 Dec 2025)"},{"key":"846_CR39","unstructured":"Inpefa (Sotagliflozin), Lexicon Pharmaceuticals, Drug Trials Snapshots (2023) U.S. Food and Drug Administration. [Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-inpefa (accessed on 9 Dec 2025)"},{"key":"846_CR40","unstructured":"INVOKANA (canagliflozin) Prescribing Information. U.S. FDA Website. [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204042s011lbl.pdf (accessed on 9 Dec 2025)"},{"issue":"8","key":"846_CR41","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1349-7006.2001.tb01175.x","volume":"92","author":"N Ishikawa","year":"2001","unstructured":"Ishikawa N, Oguri T, Isobe T, Fujitaka K, Kohno N (2001) SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res 92(8):874\u2013879","journal-title":"Jpn J Cancer Res"},{"key":"846_CR42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.18433\/jpps32879","volume":"25","author":"AM Issa","year":"2022","unstructured":"Issa AM, Bardaweel SK (2022) Exploring the role of sodium-glucose cotransporter as a new target for cancer therapy. J Pharm Pharm Sci (www cspsCanada org) 25:253\u2013265","journal-title":"J Pharm Pharm Sci (www cspsCanada org)"},{"key":"846_CR43","unstructured":"JARDIANCE\u00ae (empagliflozin) Prescribing Information. U.S. FDA Website. [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/204629s063lbl.pdf (accessed on 8 Dec 2025)"},{"issue":"20","key":"846_CR44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205237","volume":"20","author":"T Jojima","year":"2019","unstructured":"Jojima T, Wakamatsu S, Kase M, Iijima T, Maejima Y, Shimomura K et al (2019) The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma. Int J Mol Sci 20(20):5237","journal-title":"Int J Mol Sci"},{"issue":"8","key":"846_CR45","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","volume":"142","author":"K Kaji","year":"2018","unstructured":"Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K et al (2018) Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer 142(8):1712\u20131722","journal-title":"Int J Cancer"},{"issue":"4","key":"846_CR46","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/hepr.13247","volume":"49","author":"T Kawaguchi","year":"2019","unstructured":"Kawaguchi T, Nakano D, Okamura S, Shimose S, Hayakawa M, Niizeki T et al (2019) Spontaneous regression of hepatocellular carcinoma with reduction in angiogenesis-related cytokines after treatment with sodium-glucose cotransporter 2 inhibitor in a cirrhotic patient with diabetes mellitus. Hepatol Res 49(4):479\u2013486","journal-title":"Hepatol Res"},{"issue":"6","key":"846_CR47","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4093\/dmj.2021.0077","volume":"45","author":"D-S Kim","year":"2021","unstructured":"Kim D-S, Scherer PE (2021) Obesity, diabetes, and increased cancer progression. Diabetes Metab J 45(6):799\u2013812","journal-title":"Diabetes Metab J"},{"issue":"2","key":"846_CR48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/gerona\/glab254","volume":"77","author":"J Korfhage","year":"2022","unstructured":"Korfhage J, Skinner ME, Basu J, Greenson JK, Miller RA, Lombard DB (2022) Canagliflozin increases intestinal adenoma burden in female ApcMin\/+ mice. J Gerontol A 77(2):215\u2013220","journal-title":"J Gerontol A"},{"key":"846_CR49","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.12659\/MSM.902530","volume":"23","author":"H Kuang","year":"2017","unstructured":"Kuang H, Liao L, Chen H, Kang Q, Shu X, Wang Y (2017) Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma. Med Sci Monit 23:3737","journal-title":"Med Sci Monit"},{"issue":"1","key":"846_CR50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cmet.2018.08.020","volume":"29","author":"JS Lally","year":"2019","unstructured":"Lally JS, Ghoshal S, DePeralta DK, Moaven O, Wei L, Masia R et al (2019) Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab 29(1):174\u201382. e5","journal-title":"Cell Metab"},{"issue":"4","key":"846_CR51","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s11154-021-09675-9","volume":"22","author":"KT Lau","year":"2021","unstructured":"Lau KT, Ng L, Wong JW, Loong HH, Chan WW, Lee CH et al (2021) Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment\u2013a review. Rev Endocr Metab Disord 22(4):1121\u20131136","journal-title":"Rev Endocr Metab Disord"},{"key":"846_CR52","volume":"7","author":"H Li","year":"2017","unstructured":"Li H, Tong CW-S, Leung Y, Wong M-H, To KK-W, Leung K-S (2017) Identification of clinically approved drugs indacaterol and canagliflozin for repurposing to treat epidermal growth factor tyrosine kinase inhibitor-resistant lung cancer. Front Oncol 7:288","journal-title":"Front Oncol"},{"issue":"8","key":"846_CR53","volume":"20","author":"H Liu","year":"2025","unstructured":"Liu H, Guo GM, Yu ZW, Lin YL, Lin CH, Liu MM (2025) A paper-based human kidney proximal tubule-on-a-chip for efficacy of SGLT2 inhibitors and methotrexate-induced nephrotoxicity assessment. Biotechnol J 20(8):e70099","journal-title":"Biotechnol J"},{"issue":"24","key":"846_CR54","volume":"22","author":"J Luo","year":"2021","unstructured":"Luo J, Sun P, Zhang X, Lin G, Xin Q, Niu Y et al (2021) Canagliflozin modulates hypoxia-induced metastasis, angiogenesis and glycolysis by decreasing HIF-1\u03b1 protein synthesis via AKT\/mTOR pathway. Int J Mol Sci 22(24):13336","journal-title":"Int J Mol Sci"},{"key":"846_CR55","doi-asserted-by":"crossref","DOI":"10.1177\/09603271231193392","volume":"42","author":"MM Mahmoud Refaie","year":"2023","unstructured":"Mahmoud Refaie MM, Bayoumi AM, Mokhemer SA, Shehata S, Abd El-Hameed NM (2023) Role of hypoxia inducible factor\/vascular endothelial growth factor\/endothelial nitric oxide synthase signaling pathway in mediating the cardioprotective effect of dapagliflozin in cyclophosphamide-induced cardiotoxicity. Hum Exp Toxicol 42:09603271231193392","journal-title":"Hum Exp Toxicol"},{"issue":"21","key":"846_CR56","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJ McMurray","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008","journal-title":"N Engl J Med"},{"key":"846_CR57","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/DDDT.S485755","volume":"Volume 19","author":"X Miao","year":"2025","unstructured":"Miao X, Zhang J, Huang W, Wang Y, Jin A, Cao J et al (2025) Research progress of SGLT2 inhibitors in cancer treatment. Drug Des Devel Ther Volume 19:505\u2013514","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"846_CR58","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1159\/000527123","volume":"95","author":"BS Miller","year":"2022","unstructured":"Miller BS, Rogol AD, Rosenfeld RG (2022) The history of the insulin-like growth factor system. Horm Res Paediatr 95(6):619\u2013630","journal-title":"Horm Res Paediatr"},{"issue":"4","key":"846_CR59","doi-asserted-by":"crossref","first-page":"184","DOI":"10.37349\/emed.2020.00013","volume":"1","author":"A Milluzzo","year":"2020","unstructured":"Milluzzo A, Vigneri P, Martorana F, Vigneri R, Sciacca L (2020) Type 2 diabetes and cancer: problems and suggestions for best patient management. Explor Med 1(4):184\u2013204","journal-title":"Explor Med"},{"issue":"5","key":"846_CR60","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","volume":"16","author":"M Monami","year":"2014","unstructured":"Monami M, Nardini C, Mannucci E (2014) Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 16(5):457\u2013466","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"846_CR61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232283","volume":"15","author":"D Nakano","year":"2020","unstructured":"Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T (2020) Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS One 15(4):e0232283","journal-title":"PLoS One"},{"key":"846_CR62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175565","volume":"943","author":"LV Nalla","year":"2023","unstructured":"Nalla LV, Khairnar A (2023) Empagliflozin mediated miR-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer. Eur J Pharmacol 943:175565","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"846_CR63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","volume":"7","author":"AR Nasiri","year":"2019","unstructured":"Nasiri AR, Rodrigues MR, Li Z, Leitner BP, Perry RJ (2019) SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. Cancer Metab 7(1):10","journal-title":"Cancer Metab"},{"issue":"1","key":"846_CR64","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","volume":"19","author":"L Ni","year":"2020","unstructured":"Ni L, Yuan C, Chen G, Zhang C, Wu X (2020) SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol 19(1):98","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"846_CR65","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25030495","volume":"25","author":"J Okada","year":"2020","unstructured":"Okada J, Yamada E, Saito T, Yokoo H, Osaki A, Shimoda Y et al (2020) Dapagliflozin inhibits cell adhesion to collagen I and IV and increases ectodomain proteolytic cleavage of DDR1 by increasing ADAM10 activity. Molecules 25(3):495","journal-title":"Molecules"},{"issue":"4","key":"846_CR66","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s11307-025-02029-w","volume":"27","author":"K Ortmeyer Welch","year":"2025","unstructured":"Ortmeyer Welch K, McGovern KA, Chen L, Krouse R, Guo K, Huang J et al (2025) Preclinical evaluation of novel SGLT2-targeted near-infrared optical imaging agent for early-stage pulmonary adenocarcinoma. Mol Imaging Biol 27(4):558\u2013569","journal-title":"Mol Imaging Biol"},{"issue":"15","key":"846_CR67","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"},{"issue":"3","key":"846_CR68","volume":"17","author":"A Pandey","year":"2025","unstructured":"Pandey A, Alcaraz M Jr, Saggese P, Soto A, Gomez E, Jaldu S et al (2025) Exploring the role of SGLT2 inhibitors in cancer: mechanisms of action and therapeutic opportunities. Cancer 17(3):466","journal-title":"Cancer"},{"issue":"4","key":"846_CR69","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.neo.2021.02.003","volume":"23","author":"D Papadopoli","year":"2021","unstructured":"Papadopoli D, Uchenunu O, Palia R, Chekkal N, Hulea L, Topisirovic I et al (2021) Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. Neoplasia 23(4):391\u2013399","journal-title":"Neoplasia"},{"issue":"1","key":"846_CR70","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40170-023-00306-2","volume":"11","author":"LK Park","year":"2023","unstructured":"Park LK, Lim K-H, Volkman J, Abdiannia M, Johnston H, Nigogosyan Z et al (2023) Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study. Cancer Metab 11(1):6","journal-title":"Cancer Metab"},{"issue":"8","key":"846_CR71","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.tibs.2014.06.005","volume":"39","author":"KC Patra","year":"2014","unstructured":"Patra KC, Hay N (2014) The pentose phosphate pathway and cancer. Trends Biochem Sci 39(8):347\u2013354","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"846_CR72","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB (2016) The emerging hallmarks of cancer metabolism. Cell Metab 23(1):27\u201347","journal-title":"Cell Metab"},{"key":"846_CR73","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115347","volume":"164","author":"L Peng","year":"2025","unstructured":"Peng L, Zou Z, Zhou L, Li L, Lu W, Chen C et al (2025) Canagliflozin inhibits hepatic stellate cells activation and proliferation by inhibiting PP2A-mediated \u03b2-catenin dephosphorylation to attenuate hepatic fibrosis. Int Immunopharmacol 164:115347","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"846_CR74","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrc2536","volume":"8","author":"M Pollak","year":"2008","unstructured":"Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915\u2013928","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"846_CR75","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A et al (2021) The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol 20(1):150","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"846_CR76","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/cts.12549","volume":"11","author":"S Raje","year":"2018","unstructured":"Raje S, Callegari E, Sahasrabudhe V, Vaz A, Shi H, Fluhler E et al (2018) Novel application of the two-period microtracer approach to determine absolute oral bioavailability and fraction absorbed of ertugliflozin. Clin Transl Sci 11(4):405\u2013411","journal-title":"Clin Transl Sci"},{"issue":"2","key":"846_CR77","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.12578","volume":"18","author":"S Rajeev","year":"2016","unstructured":"Rajeev S, Cuthbertson D, Wilding J (2016) Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obes Metab 18(2):125\u2013134","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"846_CR78","doi-asserted-by":"crossref","first-page":"16R","DOI":"10.1093\/glycob\/cwi053","volume":"15","author":"R Ramasamy","year":"2005","unstructured":"Ramasamy R, Vannucci SJ, Yan SSD, Herold K, Yan SF, Schmidt AM (2005) Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15(7):16R\u201328R","journal-title":"Glycobiology"},{"issue":"1","key":"846_CR79","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s43188-023-00204-1","volume":"40","author":"MMM Refaie","year":"2024","unstructured":"Refaie MMM, Shehata S, El-Hussieny M, Fawzy MA, Ahmed NZM, Marey H et al (2024) Molecular mechanism of empagliflozin cardioprotection in 5-fluorouracil (5-FU)-induced cardiotoxicity via modulation of SGLT2 and TNF\u03b1\/TLR\/NF-\u03baB signaling pathway in rats. Toxicol Res 40(1):139\u2013151","journal-title":"Toxicol Res"},{"key":"846_CR80","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.canlet.2021.07.035","volume":"519","author":"D Ren","year":"2021","unstructured":"Ren D, Sun Y, Zhang D, Li D, Liu Z, Jin X et al (2021) SGLT2 promotes pancreatic cancer progression by activating the hippo signaling pathway via the hnRNPK-YAP1 axis. Cancer Lett 519:277\u2013288","journal-title":"Cancer Lett"},{"key":"846_CR81","volume":"983","author":"K Ren","year":"2024","unstructured":"Ren K, Wang X, Ma R, Chen H, Min T, Ma Y et al (2024) Dapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination. Eur J Pharmacol 983:177002","journal-title":"Eur J Pharmacol"},{"key":"846_CR82","first-page":"100759","volume":"34","author":"LA Rodriguez","year":"2024","unstructured":"Rodriguez LA, Finertie H, Neugebauer RS, Gosiker B, Thomas TW, Karter AJ et al (2024) Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Lancet Reg Health\u2013Am 34:100759","journal-title":"Lancet Reg Health\u2013Am"},{"issue":"12","key":"846_CR83","volume":"12","author":"P Saggese","year":"2020","unstructured":"Saggese P, Sellitto A, Martinez CA, Giurato G, Nassa G, Rizzo F et al (2020) Metabolic regulation of epigenetic modifications and cell differentiation in cancer. Cancer 12(12):3788","journal-title":"Cancer"},{"issue":"2","key":"846_CR84","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/0008-5472.CAN-23-1148","volume":"84","author":"P Saggese","year":"2024","unstructured":"Saggese P, Pandey A, Alcaraz M Jr, Fung E, Hall A, Yanagawa J et al (2024) Glucose deprivation promotes pseudohypoxia and dedifferentiation in lung adenocarcinoma. Cancer Res 84(2):305\u2013327","journal-title":"Cancer Res"},{"issue":"30","key":"846_CR85","doi-asserted-by":"crossref","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","volume":"112","author":"C Scafoglio","year":"2015","unstructured":"Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N et al (2015) Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci 112(30):E4111\u2013E41E9","journal-title":"Proc Natl Acad Sci"},{"issue":"467","key":"846_CR86","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat5933","volume":"10","author":"CR Scafoglio","year":"2018","unstructured":"Scafoglio CR, Villegas B, Abdelhady G, Bailey ST, Liu J, Shirali AS et al (2018) Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med 10(467):eaat5933","journal-title":"Sci Transl Med"},{"issue":"2","key":"846_CR87","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.16","volume":"2","author":"L Seman","year":"2013","unstructured":"Seman L, Macha S, Nehmiz G, Simons G, Ren B, Pinnetti S et al (2013) Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev 2(2):152\u2013161","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9933","key":"846_CR88","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(14)60886-2","volume":"383","author":"Y Shi","year":"2014","unstructured":"Shi Y, Hu FB (2014) The global implications of diabetes and cancer. Lancet 383(9933):1947\u20131948","journal-title":"Lancet"},{"issue":"1","key":"846_CR89","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41598-018-19658-7","volume":"8","author":"K Shiba","year":"2018","unstructured":"Shiba K, Tsuchiya K, Komiya C, Miyachi Y, Mori K, Shimazu N et al (2018) Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep 8(1):2362","journal-title":"Sci Rep"},{"issue":"2","key":"846_CR90","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10571-022-01221-8","volume":"43","author":"K Shoda","year":"2023","unstructured":"Shoda K, Tsuji S, Nakamura S, Egashira Y, Enomoto Y, Nakayama N et al (2023) Canagliflozin inhibits glioblastoma growth and proliferation by activating AMPK. Cell Mol Neurobiol 43(2):879\u2013892","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"846_CR91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40959-024-00284-4","volume":"11","author":"C Simela","year":"2025","unstructured":"Simela C, Walker JM, Ghosh AK, Chen DH (2025) SGLT2 inhibitors for prevention and management of cancer treatment-related cardiovascular toxicity: a review of potential mechanisms and clinical insights. Cardio-Oncology 11(1):15","journal-title":"Cardio-Oncology"},{"issue":"7","key":"846_CR92","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41573-019-0019-2","volume":"18","author":"GR Steinberg","year":"2019","unstructured":"Steinberg GR, Carling D (2019) AMP-activated protein kinase: the current landscape for drug development. Nat Rev Drug Discov 18(7):527\u2013551","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"846_CR93","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ijc.25990","volume":"130","author":"N Tasevska","year":"2012","unstructured":"Tasevska N, Jiao L, Cross AJ, Kipnis V, Subar AF, Hollenbeck A et al (2012) Sugars in diet and risk of cancer in the NIH-AARP diet and health study. Int J Cancer 130(1):159\u2013169","journal-title":"Int J Cancer"},{"issue":"3","key":"846_CR94","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","volume":"32","author":"I Tomita","year":"2020","unstructured":"Tomita I, Kume S, Sugahara S, Osawa N, Yamahara K, Yasuda-Yamahara M et al (2020) SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab 32(3):404\u201319. e6","journal-title":"Cell Metab"},{"issue":"12","key":"846_CR95","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1507\/endocrj.EJ15-0396","volume":"62","author":"S Tsugumichi","year":"2015","unstructured":"Tsugumichi S, Shuichi O, Eijiro Y, Yoko S, Aya O, Yuko T et al (2015) Effect of dapagliflozin on colon cancer cell. Endocr J 62(12):1133\u20131137","journal-title":"Endocr J"},{"issue":"1","key":"846_CR96","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","volume":"23","author":"M Tufail","year":"2024","unstructured":"Tufail M, Jiang C-H, Li N (2024) Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol Cancer 23(1):203","journal-title":"Mol Cancer"},{"key":"846_CR97","unstructured":"U.S. FDA Website. FARXIGA\u00ae (dapagliflozin) Prescribing Information. [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202293s020lbl.pdf (accessed on 8 Dec 2025)"},{"issue":"4","key":"846_CR98","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ (2017) Understanding the intersections between metabolism and cancer biology. Cell 168(4):657\u2013669","journal-title":"Cell"},{"issue":"5930","key":"846_CR99","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029\u20131033","journal-title":"Science"},{"issue":"10","key":"846_CR100","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","volume":"5","author":"LA Villani","year":"2016","unstructured":"Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE et al (2016) The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab 5(10):1048\u20131056","journal-title":"Mol Metab"},{"issue":"1","key":"846_CR101","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12935-022-02496-z","volume":"22","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yang L, Mao L, Zhang L, Zhu Y, Xu Y et al (2022) SGLT2 inhibition restrains thyroid cancer growth via G1\/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways. Cancer Cell Int 22(1):74","journal-title":"Cancer Cell Int"},{"issue":"2","key":"846_CR102","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91(2):733\u2013794","journal-title":"Physiol Rev"},{"issue":"6","key":"846_CR103","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41419-022-04980-w","volume":"13","author":"W Wu","year":"2022","unstructured":"Wu W, Zhang Z, Jing D, Huang X, Ren D, Shao Z et al (2022) SGLT2 inhibitor activates the STING\/IRF3\/IFN-\u03b2 pathway and induces immune infiltration in osteosarcoma. Cell Death Dis 13(6):523","journal-title":"Cell Death Dis"},{"key":"846_CR104","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2020.09.005","volume":"495","author":"Z Xie","year":"2020","unstructured":"Xie Z, Wang F, Lin L, Duan S, Liu X, Li X et al (2020) An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells. Cancer Lett 495:200\u2013210","journal-title":"Cancer Lett"},{"issue":"5","key":"846_CR105","first-page":"1223","volume":"57","author":"D Xu","year":"2020","unstructured":"Xu D, Zhou Y, Xie X, He L, Ding J, Pang S et al (2020) Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter-1 and lactate dehydrogenase A. Int J Oncol 57(5):1223\u20131233","journal-title":"Int J Oncol"},{"issue":"4","key":"846_CR106","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13340-021-00494-6","volume":"12","author":"L Yamamoto","year":"2021","unstructured":"Yamamoto L, Yamashita S, Nomiyama T, Kawanami T, Hamaguchi Y, Shigeoka T et al (2021) Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro. Diabetol Int 12(4):389\u2013398","journal-title":"Diabetol Int"},{"key":"846_CR107","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113856","volume":"175","author":"J Zhong","year":"2020","unstructured":"Zhong J, Sun P, Xu N, Liao M, Xu C, Ding Y et al (2020) Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin. Biochem Pharmacol 175:113856","journal-title":"Biochem Pharmacol"},{"key":"846_CR108","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110821","volume":"132","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhu J, Yu S-J, Ma H-L, Chen J, Ding X-F et al (2020) Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway. Biomed Pharmacother 132:110821","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"846_CR109","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/FPC.0000000000000268","volume":"27","author":"H Zimdahl","year":"2017","unstructured":"Zimdahl H, Haupt A, Brendel M, Bour L, Machicao F, Salsali A et al (2017) Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes. Pharmacogenet Genomics 27(4):135\u2013142","journal-title":"Pharmacogenet Genomics"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:08:35Z","timestamp":1791490115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":109,"URL":"https:\/\/doi.org\/10.1007\/164_2026_846","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"9 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}